Abstract

Background: In recent years, the prevalence of obesity has climbed sharply. Still, only a few safe and effective medications are approved as weight-loss drugs. Objective: This study aims to assess the knowledge and practice of community pharmacists in Iraq regarding the use of Liraglutide and Semaglutide as weight-loss medications. Method: A cross-sectional survey was implemented using a validated questionnaire and a convenient sample of Iraqi community pharmacists from different governorates. The questionnaire was created after conducting a literature review of the most important articles about liraglutide and semaglutide. The questionnaire consists of three sections. The first part was used to collect demographic information. The second and third parts assessed community pharmacists' knowledge and practice of the anti-diabetic weight-loss agents Liraglutide and Semaglutide, respectively. Results: A total of 225 community pharmacists participated in this survey. The mean number of successfully answered knowledge questions by all participants was 15 out of 20, indicating a good knowledge of the Iraqi community pharmacists regarding using Liraglutide and Semaglutide as weight-loss medications. The current study revealed that the mean score for the practice section is 3.97, indicating that the participating pharmacists have good practice regarding using these medications. Conclusions: Community pharmacists have demonstrated adequate knowledge about correct administration escalation, storage, adverse effects, and other aspects of using Liraglutide and Semaglutide for weight loss. There is a knowledge gap between younger and older pharmacists.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.